Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.00 Consensus Price Target from Analysts

Clearside Biomedical, Inc. (NASDAQ:CLSDGet Free Report) has been assigned a consensus recommendation of “Buy” from the four analysts that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.00.

Several brokerages recently weighed in on CLSD. StockNews.com upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Tuesday, November 14th.

Check Out Our Latest Stock Analysis on Clearside Biomedical

Clearside Biomedical Stock Performance

Shares of CLSD stock opened at $1.39 on Tuesday. Clearside Biomedical has a fifty-two week low of $0.65 and a fifty-two week high of $1.54. The firm has a market capitalization of $88.42 million, a PE ratio of -2.28 and a beta of 2.28. The stock’s 50-day simple moving average is $1.33 and its 200-day simple moving average is $1.06.

Insider Activity

In related news, major shareholder Bradford T. Whitmore purchased 444,444 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were purchased at an average price of $1.35 per share, with a total value of $599,999.40. Following the purchase, the insider now owns 4,495,034 shares of the company’s stock, valued at $6,068,295.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 9.80% of the company’s stock.

Institutional Investors Weigh In On Clearside Biomedical

Large investors have recently bought and sold shares of the company. Balyasny Asset Management LLC acquired a new position in Clearside Biomedical in the 3rd quarter valued at $25,000. Mackenzie Financial Corp acquired a new position in shares of Clearside Biomedical during the 1st quarter valued at about $27,000. JPMorgan Chase & Co. raised its position in shares of Clearside Biomedical by 100.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,161 shares of the company’s stock valued at $27,000 after buying an additional 9,109 shares during the period. Stifel Financial Corp lifted its holdings in Clearside Biomedical by 375.6% in the second quarter. Stifel Financial Corp now owns 60,544 shares of the company’s stock valued at $68,000 after acquiring an additional 47,814 shares during the last quarter. Finally, XTX Topco Ltd grew its position in Clearside Biomedical by 125.6% in the first quarter. XTX Topco Ltd now owns 50,947 shares of the company’s stock worth $117,000 after acquiring an additional 28,366 shares during the period. 13.70% of the stock is currently owned by hedge funds and other institutional investors.

About Clearside Biomedical

(Get Free Report

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

Featured Stories

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.